🚨 New RCT Alert from the NEJM!

Can an old 💊 make a comeback in modern 💓 failure care?

📌 The DIGIT-HF trial showed that digitoxin, a cardiac glycoside with hepatic clearance, reduced the combined endpoint of all-cause death or HF hospitalization in HFrEF patients on contemporary guideline-directed therapy — including ARNI, beta-blockers, MRAs & SGLT2i.

🩺 HR = 0.82; p = 0.03 📉

👩‍⚕️ Safe in CKD, consistent benefit in women.

⚠️ Serious AEs slightly higher (4.7% vs 2.8%)

📥 NNT = 22.

💡Is it time to reconsider digitoxin in advanced HFrEF?

#CardioTwitter #HFrEF #HeartFailure #Digitoxin #NEJM #Cardiology #SGLT2i #GuidelineTherapy